Insights Archive
Filter by:
November 3, 2024
Humira® biosimilars in focus
For years, Humira® (adalimumab) has been a significant driver of healthcare costs due to its high price and utilization. With the introduction of several Humira biosimilars, learn how ClearScript has been monitoring the landscape and adapting strategies to provide members access to cost-effective therapy options for better health.